VEGFA and neoplasm: The limited responses and acquired resistance to anti-VEGF therapy suggest that while angiogenesis through VEGF is an important target for cancer therapies, the development of successful new drugs will require a deeper understanding of factors that facilitate escape from anti-angiogenic therapy and allow for continued tumor survival and vascularization.